InflaRx (NASDAQ:IFRX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of InflaRx (NASDAQ:IFRX) in a report published on Monday morning, Benzinga reports. They currently have a $8.00 price objective on the stock.

InflaRx Stock Performance

InflaRx stock opened at $1.60 on Monday. The business’s 50-day simple moving average is $1.45 and its two-hundred day simple moving average is $1.55. The company has a market cap of $94.21 million, a PE ratio of -2.05 and a beta of 1.20. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $4.61.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.05. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $1.76 million. As a group, analysts predict that InflaRx will post -0.81 EPS for the current fiscal year.

Institutional Trading of InflaRx

Several large investors have recently added to or reduced their stakes in IFRX. Raymond James & Associates boosted its stake in shares of InflaRx by 7.9% in the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company’s stock worth $286,000 after buying an additional 12,873 shares during the last quarter. 683 Capital Management LLC boosted its stake in shares of InflaRx by 17.5% in the third quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock worth $7,003,000 after buying an additional 350,000 shares during the last quarter. Alps Advisors Inc. boosted its stake in shares of InflaRx by 109.4% in the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after buying an additional 43,501 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in shares of InflaRx by 18.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company’s stock worth $518,000 after buying an additional 48,944 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in shares of InflaRx by 35.3% in the third quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock worth $969,000 after buying an additional 84,897 shares during the last quarter. Hedge funds and other institutional investors own 42.39% of the company’s stock.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.